世界製药 (2022)

Global Pharmaceutical Tracker, 2022

出版日期: 2022年07月13日 | 出版商:

Frost & Sullivan | 英文 22 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

预计全球製药市场将通过专注于药物发现和开发的数字合作伙伴关係推动未来增长。

由于数字化内爆，製药公司的商业模式正在发生变化，以实现数字化成熟。大型製药公司正在与技术供应商合作，以加速数字化并降低对内部能力、平台和解决方案的投资风险。研发渠道下降、过去二十年来生产力停滞不前以及大流行导致临床试验中断，导致合作伙伴关係激增。

本报告探讨了全球製药市场，并全面讨论了 2022 年的主要製药行业批准、併购、产品许可交易和数字合作伙伴关係。

内容

执行摘要

主要亮点
製药行业 - 值得关注的公司

新模式的批准（2022 年第一季度）

批准新模式

併购（2022 年第一季度）

重大併购

关键的许可和许可协议（2022 年第一季度）

主要的入许可和出许可协议

关键数字合作伙伴（2022 年第一季度）

数字合作
免责声明

简介目录

Product Code: K6F0-50

Digital Partnerships Focused on Drug Discovery and Development Drive Future Growth Potential

This research service offers comprehensive discussions about the key approvals, mergers and acquisitions, product licensing deals, and digital partnerships of the pharmaceutical industry in 2022. A renewed focus on operational excellence and digital transformation will push top-line pharmaceutical industry growth and drive strong partnerships with small and mid-size pharma and digital solution vendors.

The digital implosion is transforming the pharma business model to achieve digital maturity. Big pharma is moving toward technology vendor partnerships to accelerate digitization and de-risk investments in in-house capabilities, platforms, and solutions. Diminishing R&D pipelines, stagnant productivity during the last 2 decades, and the disruption in clinical trials due to the pandemic have led to a surge in partnerships. Small and mid-sized companies will continue to attract big pharma and private equity (PE) firms. New modalities and technologies will remain attractive for licensing deals, giving biotech licensor candidates a higher chance of negotiating contract terms and up-front payments.